Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/13/2020 01/14/2020 01/15/2020 01/16/2020 01/17/2020 Date
138.94(c) 140.65(c) 141.11(c) 141.43(c) 139.58(c) Last
5 117 116 4 685 251 3 676 480 3 794 808 5 393 587 Volume
+0.68% +1.23% +0.33% +0.23% -1.31% Change
More quotes
Financials (USD)
Sales 2019 22 139 M
EBIT 2019 6 018 M
Net income 2019 8 052 M
Debt 2019 12 303 M
Yield 2019 1,82%
Sales 2020 23 729 M
EBIT 2020 7 313 M
Net income 2020 5 346 M
Debt 2020 11 023 M
Yield 2020 2,06%
P/E ratio 2019 16,4x
P/E ratio 2020 22,8x
EV / Sales2019 6,61x
EV / Sales2020 6,11x
Capitalization 134 B
More Financials
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (17.4%); - veterinary medicine (12.8%); - cardiovascular... 
Sector
Pharmaceuticals
Calendar
01/30 | 06:25amEarnings Release
More about the company
Surperformance© ratings of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on ELI LILLY AND COMPANY
08:39aNigeria's booming market for hypertension care
AQ
01/20BNP Paribas AM Launches World Climate Carbon Offset Plan Fund
DJ
01/17Health Executives Brace for Change In Regulation and Competition -- WSJ
DJ
01/16DERMIRA : Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - C..
RE
01/16ELI LILLY AND : Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 ..
PR
01/16Health Executives Gear Up for Change at J.P. Morgan Conference
DJ
01/16ELI LILLY AND : Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase..
AQ
01/15ELI LILLY AND : Lilly expands insulin affordability options with lower-priced ve..
AQ
01/14ELI LILLY AND COMPANY : - Tyvyt Combined with ALIMTA and Platinum Met Predefined..
AQ
01/14ELI LILLY AND : Lilly expands insulin affordability options with lower-priced ve..
PR
01/13ELI LILLY AND : Lilly Announces Agreement to Acquire Dermira
AQ
01/13ELI LILLY, INNOVENT : Tyvyt Combo Meets Main Endpoint in Phase 3 Study
DJ
01/13ELI LILLY AND : Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed)..
PR
01/12ELI LILLY AND : Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) a..
PR
01/10ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc.
PR
More news
News in other languages on ELI LILLY AND COMPANY
01/17DKSH und Eli Lilly setzen auf Partnerschaft in Singapur
01/14ELI LILLY : options économiques pour deux insulines
01/13ELI LILLY : résultats d'une étude de phase 3 en Chine
01/10Les valeurs à suivre vendredi 10 janvier 2020 à Paris -
01/10ELI LILLY : rachète Dermira pour 1,1 milliard de dollars en cash
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
08:54aGoodwill Sparks Deep Division, at Least on Balance Sheets
DJ
07:44aMyriad Submits sPMA for BRACAnalysis CDx Test
DJ
07:29aAstraZeneca, Merck Get FDA Priority Review for Lynparza in Form of Prostate C..
DJ
01/20JPMorgan says 'oui' to Paris expansion post-Brexit
RE
01/20ALLERGAN : Form 8.3 - Allergan Plc
DJ
More sector news : Pharmaceuticals - NEC
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 139,64  $
Last Close Price 139,58  $
Spread / Highest target 18,2%
Spread / Average Target 0,05%
Spread / Lowest Target -19,0%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Myles Oneill Senior VP & President-Manufacturing Operations
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY6.20%134 015
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 068
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%216 654